Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Masoprocol for multiple actinic keratoses

Article Abstract:

Actinic keratoses, a skin disease resulting from chronic ultraviolet light exposure, can be treated with Actinex. Actinex is a topical cream containing 10% masoprocol. In a clinical trial of 113 patients, 50% percent of actinic keratoses patients who applied masoprocol twice daily for 14 to 28 days showed marked improvement and 11% were cured. The recommended treatment is twice daily application for 28 days. Adverse effects, leading to the exclusion of 25 patients in the trial, included erythema, a reddening or inflammation of the skin; itching, flaking, burning and soreness; edema; and allergic dermatitis. The longterm effects of the cream require further study. Actinex costs pharmacists $48 for 30 grams, which is slightly more expensive than the leading fluorouracil topical treatment. but causes less severe reactions.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1993
Evaluation, Drug therapy, Actinex (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Epinastine ophthalmic solution (ELESTAT)

Article Abstract:

Epinastine HCl an H (sub 1)-receptor antagonist and most cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution for prevention of itching associated with allergic conjunctivitis. The most important thing is that contact lenses should be removed before and they can be reinserted ten minutes later.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2004
Allergy, Allergic reaction, Ophthalmic solutions

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Imiquimod (Aldara) for actinic keratoses

Article Abstract:

The approval of imiquimod cream 5 percent (Aldara - 3M) by the FDA is discussed. The drug is useful for treating actinic keratoses (AKs) on the face or scalp and also acts on subclinical and clinically detectable lesions.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2004
United States, Usage, Imiquimod

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Actinic keratosis, Care and treatment, Licensing, certification and accreditation, United States. Food and Drug Administration
Similar abstracts:
  • Abstracts: The multiple endocrine neoplasia syndromes. Therapeutic use of calcimimetics. Inherited disease involving G proteins and G protein-coupled receptors
  • Abstracts: Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia
  • Abstracts: Can curcumin cure cystic fibrosis?. Homocysteine lowering with folic acid and B vitamins in vascular disease. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis
  • Abstracts: Home treatment for women with stress urinary incontinence. Vaginal cones in stress incontinence treatment. Plantar fasciitis
  • Abstracts: Awareness and prevention error in clinical decision-making. Learning how to communicate better with deafened patients
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.